LEADER showed a 13% reduction in the primary outcome of major adverse cardiovascular events (MACE) with liraglutide vs
Berridge KC, Robinson TE (1998)
That is my staple
Particularly, the background anti-diabetic agents, lipid-lowering drugs, antiaggregants, and antihypertensives may affect cardiovascular events
PubMed Klicek, R., Kolenc, D., Suran, J., Drmic, D., Brcic, L., Aralica, G., Sever, M., Holjevac, J., Radic, B., Turudic, T., Kokot, A., Patrlj, L., Rucman, R., Seiwerth, S., & Sikiric, P
"There are basically no published human efficacy trials for BPC-157." Phillips says all he can find is one small safety study from a decade ago, and a trial that only started enrolling participants this past February